The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: A CTF study

被引:14
|
作者
Gadducci, A
Landoni, F
Maggino, T
Sartori, E
Zola, P
Fanucchi, A
机构
[1] UNIV MILAN,BRANCH 3,DEPT OBSTET & GYNECOL,MONZA,MILANO,ITALY
[2] UNIV PADUA,DEPT OBSTET & GYNECOL,PADUA,ITALY
[3] UNIV BRESCIA,DEPT OBSTET & GYNECOL,BRESCIA,ITALY
[4] UNIV TURIN,DEPT OBSTET & GYNECOL,TURIN,ITALY
关键词
D O I
10.1006/gyno.1996.0312
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This retrospective study assessed 46 patients with advanced ovarian cancer who had elevated preoperative serum CA 125 (>35 U/ml) and who had another serum CA 125 assay 6-9 days after surgery, Preoperative CA 125 levels were similar in patients with residual disease below 20 mm and in those with larger residuum, The postoperative decline of serum CA 125 was significantly higher in patients with small residual disease at any preoperative serum CA 125 value, By taking 60% as the cutoff of CA 125 decline, the diagnostic accuracy of this parameter in discriminating between patients with residual disease below or above 20 mm improved progressively when we considered patients with increasing preoperative antigen values, However, even in the subset of patients with preoperative serum CA 125 above 400 U/ml, 2 of the 20 patients with less than 20 mm residual disease had a percentage reduction of antigen levels lower than 60%, whereas 5 of the 10 patients with larger than 20 mm residuum had a CA 125 decline higher than 60%. Therefore, we believe that the perioperative changes of CA 125 levels have a limited clinical relevance in the mangagement of patients with ovarian cancer. (C) 1996 Academic Press, Inc.
引用
收藏
页码:234 / 237
页数:4
相关论文
共 50 条
  • [31] The relevance of rising CA-125 levels within the normal range in predicting recurrence in patients with advanced stage ovarian cancer: A validation study
    AbuShain, F.
    Escobar, P.
    Shahabi, S.
    Michener, C.
    Drake, R.
    Rose, P. G.
    Schwartz, P. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Prognostic significance of combined CA 125 and TPS levels after chemotherapy in ovarian cancer patients. Preliminary results of a multicenter study
    VanDalen, A
    Baumgartner, L
    DeBruijn, H
    Dombi, VH
    Fink, D
    Giai, M
    McGing, P
    Hasholzner, U
    Harlozinska, A
    Kainz, CH
    Markowska, J
    Molina, R
    Sturgeon, C
    Einarsson, R
    10TH INTERNATIONAL MEETING OF GYNAECOLOGICAL ONCOLOGY, 1997, : 291 - 295
  • [33] CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
    Furukawa, Naoto
    Sasaki, Yoshikazu
    Shigemitsu, Aiko
    Akasaka, Juria
    Kanayama, Seiji
    Kawaguchi, Ryuji
    Kobayashi, Hiroshi
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) : 141 - 145
  • [34] Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study
    Feng, Li-Yuan
    Liao, Sheng-bin
    Li, Li
    JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [35] Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study
    Li-yuan Feng
    Sheng-bin Liao
    Li Li
    Journal of Ovarian Research, 13
  • [36] Prediction of a non-rising increase of serum CA-125 levels during chemotherapy treatment in recurrent patients of advanced epithelial ovarian cancer after reviously being treated optimally
    Lee, S. H.
    Roh, H. J.
    Kwon, Y. S.
    Lee, S. J.
    Ahn, J. W.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 755 - 755
  • [37] Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma
    Zeng, Jing
    Yin, Jie
    Song, Xiao
    Jin, Ying
    Li, Yan
    Pan, Lingya
    JOURNAL OF CANCER, 2016, 7 (15): : 2327 - 2332
  • [38] A STUDY OF THE NB/70K AND CA 125 MONOCLONAL-ANTIBODY RADIOIMMUNOASSAYS FOR MEASURING SERUM ANTIGEN LEVELS IN OVARIAN-CANCER PATIENTS
    KNAUF, S
    ANDERSON, DJ
    KNAPP, RC
    BAST, RC
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 152 (07) : 911 - 913
  • [39] CA-125 SERUM LEVELS CORRELATE WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS - A PROSPECTIVE MULTIINSTITUTIONAL STUDY
    BEREK, J
    KNAPP, R
    MALKASIAN, G
    LAVIN, P
    HACKER, N
    WHITNEY, C
    NILOFF, J
    BAST, R
    GYNECOLOGIC ONCOLOGY, 1986, 23 (02) : 260 - 261
  • [40] Changes of CA125 Can Predict Cytoreduced to No Visible Residual Disease and Platinum-sensitive in Patients with Advanced Epithelial Ovarian Cancer Treated with Neoadjuvant Chemotherapy
    Zeng, J.
    Jin, Y.
    Li, Y.
    Song, X.
    Yin, J.
    Pan, L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 863 - 864